Bristol Myers Squibb on Thursday reported better quarterly results than expected, but poor instructions for 2025 sent lower shares. Jim Cramer’s trust in the drug manufacturer is steadfast. Revenue in the fourth quarter increased 8% year by year $ 12.34 billion, much before the $ 11.57 billion consensus, according to Analyst compiled by LSEG. A share -regulated profits (EPS) of $ 1.67 in three months that ended on December 31 Ratches headed by $ 1.46, LSEG data showed. On the annual basis, the regulated EPS fell 1.8%. Bristol Myers Squibb (BMY) Why we own it: the new Cobenfy Company’s schizophrenia treatment has a tremendous sales potential, though it remains in early beginnings. Bristol Myers have major products, such as the elliquis blood block prevention drugs and OPDIVO lung cancer therapy, which will emerge from patent in the coming years. However, we believe that its growth medication portfolio, including cobenfy, can help navigate that patent rock. Beginning: November 25, 2024 Most Purchase Date: January 17, 2025 Competitors: Abbvie, Pfizer, Amgen, Johnson & Johnson and Merck Bottom Line The Slide in Bristol Myers’ shares – down more than 4.5% in sessions below Below $ 57-is a gift for long-term investors. We are reiterating our 1-equivalent equivalent rating and the price target of $ 70 per share. Bristol Myers’s shares were later able to recover Ca, approximately 2% in late morning trade. “It’s a purchase,” Jim said in “Squawk on the street” of Cnbc on Thursday morning. “I was praying this [sell-off] It would happen so I could get inside and buy a little more. “The club cannot buy because we are limited, but that does not stop us from telling members what we were going to do. Jim later said in the morning meeting,” you have to stay there and buy that handful hand . “Bmy 1y Mountain Bristol Myers Squibb 1 essential year of our thesis in Bristol Myers is Cobenfy, the new treatment of the company’s schizophrenia that began in the SH.BA at the end of last year. Its’S’S’S OUT FOR A good start, Marked the fourth quarter of $ 10m for drugs. And so, we are with our teams, educating customers on Cobenfy’s differentiated profile, and we are breaking the habits of reflexive description, and it will take some time, “said the main commercialization official Adam Lenkowsky in the call.” Thus, we would expect to see constant strong intake by 2025 … with a ramp in the back of this year. But taken together, we are really pleased what we are seeing so far. And we plan to make this a great product for the company over time. “Expanding the recipe label in Cobenfy to include other conditions can help the medicine understand that trade potential. At that front, Bristol Myers is expecting two judicial readings this year this can serve as catalysts to run shares Higher, including a study that evaluates its effects on the psychosis of Alzheimer’s disease. Autism. The EPS of 6.55 to $ 6.85 was also easier than the $ 6.92 consensus. Which has contributed to the gap between instruction and consensus. Jim said the company has been very front on the issues of revlimid, which is why he is not very concerned. The Pomalist, another of his cancer treatments, is also dealing with a patent expiration in Europe. Indeed, executives said in the call that her portfolio of “inheritance drugs”, where his exposure to patent expirations is concentrated, is probably the blame for any guidance loss, accompanied by a head of approximately $ 500 million of foreign exchange that may not have been mature within the financial models of analysts. We also liked that management announced plans to reduce up to $ 2 billion in cost by 2027. This will probably not be the last time Bristol Myers patent rocks create noise about its results, even if it is one well documented part of the story. However, as long as Bristol Myers executes for starting the cobenfy and its broad growth portfolio, which without a 21% sales increase year by year, “continues to perform well, there are reasons for Trusted the shares can continue to work.
The OPDIVO boxes from Bristol Myers were seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, July 22, 2022.
George Frey | Reuters
Bristol Myers Squibb On Thursday, it reported better quarterly results than expected, but poor instructions for 2025 sent lower shares. Jim Cramer’s trust in the drug manufacturer is steadfast.